GlassScriptPhysician profile
Jorge L Macia
NPI 1851486468
$19,955.15
in general payments reported to CMS, 2019-2025
46 companies · $2,682 in 2025
The $2,682 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,577 · 2020: $2,164 · 2021: $4,157 · 2022: $2,372 · 2023: $2,158 · 2024: $2,844 · 2025: $2,682.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,685.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,684.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,079.48 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Abbott Laboratories | $1,979.46 | 2019-2025 | Mitraclip, Epic, Esprit |
| Bayer Healthcare Pharmaceuticals INC. | $1,768.94 | 2021-2025 | |
| Novo Nordisk INC | $1,393.45 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Janssen Pharmaceuticals, INC | $1,354.64 | 2019-2022 | |
| Esperion Therapeutics, INC. | $1,074.25 | 2020-2024 | Nexletol, Nexlizet |
| Pfizer INC. | $1,015.88 | 2019-2025 | |
| Lilly USA, LLC | $769.27 | 2019-2025 | Mounjaro, Jardiance |
| Glaxosmithkline, LLC. | $675.47 | 2020-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Amgen INC. | $621.00 | 2019-2023 | Otezla, Repatha |
| Atricure, INC. | $534.59 | 2022-2024 | |
| Abbvie INC. | $528.03 | 2019-2025 | |
| Intuitive Surgical, INC. | $389.64 | 2024 | |
| Amarin Pharma, INC. | $358.67 | 2020-2022 | |
| Phathom Pharmaceuticals, INC. | $344.63 | 2024-2025 | Voquezna |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $336.23 | 2022-2023 | Ligasure |
| Kowa Pharmaceuticals America, INC. | $277.83 | 2020-2025 | Seglentis, Zoryve, Livalo |
| Boston Scientific Corporation | $272.27 | 2019-2023 | Watchman Flx |
| United Therapeutics Corporation | $249.88 | 2021 | |
| Incyte Corporation | $239.27 | 2023-2025 | Opzelura, Opzelura |
| Silk Road Medical, INC. | $186.87 | 2022 | |
| W. L. Gore & Associates, INC. | $186.35 | 2019 | |
| Sonex Health, INC. | $157.68 | 2025 | Sx-One Microknife |
| Otsuka America Pharmaceutical, INC. | $149.07 | 2023-2024 | Rexulti, Jynarque |
| Allergan, INC. | $148.08 | 2019 | |
| Edwards Lifesciences Corporation | $145.42 | 2021 | |
| Penumbra, INC. | $144.30 | 2025 | Indigo System |
| E.R. Squibb & Sons, L.L.C. | $138.94 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $133.09 | 2019-2025 | Jardiance |
| Ani Pharmaceuticals, INC. | $125.00 | 2025 | Purified Cortrophin Gel |
| Exact Sciences Corporation | $124.16 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Mallinckrodt Enterprises LLC | $123.58 | 2019 | |
| Medtronic Vascular, INC. | $119.88 | 2020 | |
| Procept Biorobotics Corporation | $113.91 | 2023 | Aquabeam Robotic System |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $112.57 | 2019 | |
| Idorsia Pharmaceuticals US INC | $111.19 | 2023 | Quviviq |
| Ekos Corporation | $109.75 | 2019 | |
| Alkermes, INC. | $109.65 | 2024 | Lybalvi |
| Daiichi Sankyo INC. | $89.78 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $37.27 | 2019-2020 | |
| Kvk-Tech, INC. | $30.25 | 2024 | |
| Alnylam Pharmaceuticals INC. | $23.69 | 2024 | Givlaari |
| Alvogen INC | $23.18 | 2021 | |
| Arbor Pharmaceuticals, INC. | $20.87 | 2019 | |
| Eisai INC. | $16.05 | 2021 | |
| Currax Pharmaceuticals LLC | $11.69 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jorge Macia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.